Drug Insights

Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Buprenorphine

6 March 2024
2 min read

Buprenorphine Hydrochloride, a drug approved in US on December 29, 1981, is manufactured by Indivior and is primarily used to manage pain that requires opioid analgesics and for which alternative treatments are insufficient. Buprenorphine works as a partial agonist at the mu-opioid receptor and as an antagonist at the kappa-opioid receptor. Its slow rate of dissociation from its receptor, which has been observed in vitro studies, accounts for its longer duration of action compared to morphine, its unpredictability of reversal by opioid antagonists, and its low level of manifest physical dependence. Buprenex is an important drug for pain management and has been widely used in the medical field. Click on the image below to begin the exploration journey of Buprenorphine through the Synapse database!

图形用户界面, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Approves IND Submission for Atara's ATA3219, an Off-the-Shelf CAR T Therapy for Lupus Nephritis
Latest Hotspot
3 min read
FDA Approves IND Submission for Atara's ATA3219, an Off-the-Shelf CAR T Therapy for Lupus Nephritis
6 March 2024
ATA3219, an off-the-shelf CAR T treatment by Atara Biotherapeutics, gets green light from the FDA for its IND submission targeting Lupus Nephritis.
Read →
The Synapse User's Toolkit: Tips for Searching Aspirin
Drug Insights
2 min read
The Synapse User's Toolkit: Tips for Searching Aspirin
6 March 2024
Aspirin, also known as acetylsalicylic acid (ASA), is a widely used nonsteroidal anti-inflammatory drug (NSAID) that helps reduce pain, fever, and inflammation while also acting as an antithrombotic.
Read →
UK Regulators Greenlight Ariceum's Early Trial for I-123 Tagged PARP Blocker in Recurrent Glioblastoma Patients
Latest Hotspot
3 min read
UK Regulators Greenlight Ariceum's Early Trial for I-123 Tagged PARP Blocker in Recurrent Glioblastoma Patients
6 March 2024
UK regulators have approved Ariceum Therapeutics to initiate an early-stage trial with its innovative I-123 tagged PARP blocker for individuals experiencing repeated glioblastoma.
Read →
Unlock the Power of Synapse: A Guide to Searching Sucralfate
Drug Insights
2 min read
Unlock the Power of Synapse: A Guide to Searching Sucralfate
6 March 2024
Sucralfate is a medication that was first approved in Japan in February 1968 by Allergan.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.